spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  phototherapy 

 HSMN NewsFeed - 16 Jan 2025
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX(R) (bimekizumab-bkzx)
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Oct 2023
FDA Approves Novartis Cosentyx(R) as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 May 2023
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2023
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Aug 2021
SKYRIZI(R) (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2020
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2020
Sciton Unveils Newest Aesthetic Platform, mJOULE(TM) Featuring BBL HERO(TM) And MOXI(TM)
Devices Dermatology Product Launch
 HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Apr 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Mar 2020
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 3 Oct 2019
New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Aug 2019
Amgen To Acquire Otezla(R) For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2019
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz(R) (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 28 Mar 2019
Sciton Unveils New JOULE X Platfor(TM)m During ASLMS, Bringing Realtime Aesthetic Insights Into Your Hands
Devices Dermatology Product Launch
 HSMN NewsFeed - 22 Mar 2019
Sciton Announces Excellent Outcomes from Deep Perioral Er:Yag Laser Resurfacing in Multiyear Retrospective Study
Devices Dermatology
 HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 21 Nov 2018
FDA Closes Inquiry Regarding IHCTOA Letter Regarding Sciton's diVa(R) Laser
Devices Dermatology FDA
 HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 8 May 2018
Sciton Announces New Leadership Team
Devices Dermatology Personnel
 HSMN NewsFeed - 23 Feb 2018
Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2018
Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 17 Nov 2017
Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Biopharmaceuticals Devices Drug Delivery Product Launch
 HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 12 Oct 2017
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 15 Sep 2017
Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 27 Jul 2017
Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals
 HSMN NewsFeed - 21 Apr 2017
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ(TM) (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Mar 2017
U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Sep 2015
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 22 Apr 2014
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 26 Aug 2013
Ceptaris Receives FDA Approval for VALCHLOR(TM) (mechlorethamine) Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2012
Natus Comments on FDA Recall
Devices Product Recall FDA
 HSMN NewsFeed - 19 Oct 2011
IRIDEX Launches New MicroPulse(TM) Module Targeting the Broad Ophthalmology Laser Photocoagulation Market
Devices Ophthalmology
 HSMN NewsFeed - 16 Sep 2011
Natus Acquires Embla Systems LLC - Leading Sleep Diagnostic Company
Devices Mergers & Acquisitions
 HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 9 Feb 2011
Natus Medical Appoints John T. Buhler as President and COO
Devices Personnel
 HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 17 Jan 2011
T-Ray Science Announces Name Change
Devices Diagnostics Oncology
 HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals
 HSMN NewsFeed - 13 Oct 2010
Natus Acquires Medix - Leading Newborn Care Company in Latin America
Devices Mergers & Acquisitions
 HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Mar 2010
Levia(R) Brings Personal Targeted Phototherapy Home as a Treatment Option for Millions of Psoriasis Patients
Devices Dermatology
 HSMN NewsFeed - 13 Jan 2010
Natus Medical Announces Reorganization
Devices
 HSMN NewsFeed - 5 Jan 2010
Levia(R) for Personal Targeted Phototherapy(TM) Treatment of Psoriasis Receives FDA 510(k) Clearance
Devices Dermatology FDA
 HSMN NewsFeed - 14 Sep 2009
Natus Medical to Acquire Alpine Biomed
Devices Monitoring Neurology Mergers & Acquisitions
 HSMN NewsFeed - 6 Jul 2009
Natus Medical Acquires Hawaii Medical
Devices Mergers & Acquisitions
 HSMN NewsFeed - 1 Jun 2009
Introducing The Pioneering XTRAC Velocity Excimer Laser: Delivers Psoriasis And Vitiligo Treatments Three Times Faster
Devices Dermatology
 HSMN NewsFeed - 20 Apr 2009
Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth
Devices
 HSMN NewsFeed - 8 Apr 2009
Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2008
Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2008
Natus Medical to Acquire Products from BrainZ Instruments Limited
Devices Monitoring Acquisitions
 HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals
 HSMN NewsFeed - 3 Sep 2008
Natus Medical to Acquire NeuroCom International
Devices Mergers & Acquisitions
 HSMN NewsFeed - 2 Jul 2008
Natus Medical Acquires Schwarzer GmbH Neurology Division
Devices Neurology Acquisitions
 HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 5 Jun 2008
MedX(R) Announces Positive Results From Low-Level Laser Therapy Study in Wound Healing
Devices Wound Care
 HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Biopharmaceuticals
 HSMN NewsFeed - 28 May 2008
Natus Medical Completes Acquisition of Sonamed
Devices Mergers & Acquisitions
 HSMN NewsFeed - 21 May 2008
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 21 May 2008
American Academy of Dermatology Issues New Guidelines for the Management of Psoriasis and Psoriatic Arthritis
Dermatology
 HSMN NewsFeed - 13 May 2008
PhotoMedex Receives FDA Clearance for the XTRAC(R) Velocity(TM) Laser
Devices Dermatology FDA
 HSMN NewsFeed - 5 May 2008
Unique Three-Year Data Demonstrating Long-Term Efficacy and Safety of Raptiva(R) in the Treatment of Psoriasis Published in the British Journal of Dermatology
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Apr 2008
Natus Medical to Acquire SonaMed
Devices Mergers & Acquisitions
 HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2008
Data Presented at International Psoriasis Meeting Support Potential New Role for Biologic Treatment Etanercept in Management of Childhood Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Feb 2008
Natus Medical to Resume Domestic Shipments of Olympic Cool-Cap
Devices FDA Neurology
 HSMN NewsFeed - 11 Feb 2008
Natus Medical Announces Integration and Restructuring
Devices
 HSMN NewsFeed - 19 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2008
New Study Shows Biologic Therapy Enbrel(R) (etanercept) Effective in Treating Psoriasis in Children and Adolescents
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2008
New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2007
Natus Resumes Production and Shipping Operations at Olympic Facility
Devices
 HSMN NewsFeed - 10 Oct 2007
Natus Medical to Acquire Excel-Tech Ltd.
Devices Mergers & Acquisitions
 HSMN NewsFeed - 25 Jul 2007
Tru-Blu(TM) Light Treatment Approved for Acne
Devices Dermatology FDA
 HSMN NewsFeed - 24 Apr 2007
Natus Medical Signs Three-Year Supplier Contracts with Premier, Inc.
Devices Group Purchasing
 HSMN NewsFeed - 2 Feb 2007
Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Nov 2006
Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2006
ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
New Phase III Data Show Abbott's HUMIRA(R) (Adalimumab) Was Statistically Superior to Methotrexate in Patients With Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 53

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 53 additional stories matching:
phototherapy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.